☆ 4.6 Article

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma

CANCERS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Cancer statistics for African American/Black People 2022

Angela N. Giaquinto et al.

Summary: African American/Black individuals bear a disproportionate cancer burden, with high mortality and low survival rates compared to other racial/ethnic groups. Data from the American Cancer Society shows that in 2018, there were significant disparities in cancer incidence, mortality, survival, screening, and risk factors among Black people in the United States. The projected numbers for 2022 indicate a high number of new cancer cases and deaths among Black individuals. Black men have higher incidence and mortality rates for certain cancers, such as myeloma, stomach cancer, and prostate cancer. The disparity in overall cancer mortality between Black and White men is narrowing, but the decline in prostate cancer mortality among Black men has slowed. Black women have a lower incidence rate but higher mortality rates for certain cancers, such as endometrial and breast cancer. Breast cancer has become the leading cause of cancer death among Black women.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Article Oncology

Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib

Maya N. White et al.

Summary: The optimal treatment for EGFR-mutated lung cancer after progression on osimertinib remains unclear. A retrospective study was conducted to evaluate the outcomes of patients who received platinum doublet chemotherapy alone or in combination with immunotherapy or bevacizumab. The results showed that adding immunotherapy to chemotherapy resulted in worse overall survival, while the addition of bevacizumab did not significantly affect survival.

CLINICAL LUNG CANCER (2022)

添加到收藏夹

Article Oncology

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

Naoyuki Nogami et al.

Summary: This study presents the final overall survival (OS) analyses for EGFR mutations and liver or brain metastases subgroups in the IMpower150 study. The results show that ABCP has sustained OS improvements compared to BCP in sensitizing EGFR mutations and baseline liver metastases subgroups. However, ACP does not provide a survival benefit in these subgroups compared to BCP. The study also suggests further investigation into the impact of ABCP on delaying the development of new brain lesions.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Editorial Material Oncology

Chemoimmunotherapy for EGFR-Mutant NSCLC: Still No Clear Answer

Bharathi Muthusamy et al.

Summary: The past decade has witnessed significant progress in the treatment of advanced NSCLC, with the introduction of biomarker testing and targeted therapies, as well as the use of immune checkpoint inhibitors. However, the effectiveness of immune checkpoint inhibitors in patients with EGFR mutations remains controversial.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination

Jiali Yu et al.

Summary: Liver metastases diminish the efficacy of immunotherapy by siphoning activated CD8(+) T cells from systemic circulation, creating systemic immune desert. Combining liver-directed radiotherapy with immunotherapy can promote systemic antitumor immunity.

NATURE MEDICINE (2021)

添加到收藏夹

Article Oncology

OA09.03 Pembrolizumab in Combination With Platinum-Based Chemotherapy in Recurrent EGFR/ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

S. Gadgeel et al.

Journal of Thoracic Oncology (2021)

添加到收藏夹

Editorial Material Oncology

Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC

Jacqueline V. Aredo et al.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Jacqueline V. Aredo et al.

Summary: Consolidation durvalumab did not benefit patients with EGFR-mutated unresectable stage III NSCLC and was associated with a high frequency of immune related adverse events. Patients who switched to osimertinib after durvalumab treatment may be more susceptible to incident adverse events. Further investigation is needed for concurrent CRT with induction or consolidation EGFR TKIs as definitive treatment.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

MRTX-500: Phase II trial of sitravatinib (sitra) plus nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

T. A. Leal et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer

Xiaoke Liu et al.

LUNG CANCER (2020)

添加到收藏夹

Article Critical Care Medicine

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Martin Reck et al.

LANCET RESPIRATORY MEDICINE (2019)

添加到收藏夹

Article Oncology

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

Roy S. Herbst et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

J. -C. Soria et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Oncology

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

Christian Manegold et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer A Meta-Analysis

Chee Khoon Lee et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer et al.

LANCET (2017)

添加到收藏夹

Article Oncology

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

Paul C. Tumeh et al.

CANCER IMMUNOLOGY RESEARCH (2017)

添加到收藏夹

Article Oncology

Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations

Joshua D. Campbell et al.

JAMA ONCOLOGY (2017)

添加到收藏夹

Article Oncology

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

Justin F. Gainor et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst et al.

LANCET (2016)

添加到收藏夹

Article Oncology

Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer

Ming-Szu Hung et al.

ONCOLOGY LETTERS (2016)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

H. Borghaei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.